Lineage-Specific Metabolic Properties and Vulnerabilities of T Cells in the Demyelinating Central Nervous System

3-bromopyruvate ameliorate autoimmune arthritis by modulating Th17/Treg cell differentiation and suppressing dendritic cell activation

(2017) Takaichi Okano et al.   Scientific Reports

Metabolic reprogramming of alloantigen-activated T cells after hematopoietic cell transplantation

(2016) Hung D. Nguyen et al.   JOURNAL OF CLINICAL INVESTIGATION

LRP1 expression in microglia is protective during CNS autoimmunity

(2016) Tzu-Ying Chuang et al.   Acta Neuropathologica Communications

Immunology of Relapse and Remission in Multiple Sclerosis

(2014) Lawrence Steinman   Annual Review of Immunology

3-Bromopyruvic Acid, A Hexokinase II Inhibitor, is an Effective Antitumor Agent on the Hepatoma Cells : in vitro and in vivo Findings

(2014) Lei Gong et al.   Anti-Cancer Agents in Medicinal Chemistry

Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation

(2014) Valerie A. Gerriets et al.   JOURNAL OF CLINICAL INVESTIGATION

Glucose Uptake Is Limiting in T Cell Activation and Requires CD28-Mediated Akt-Dependent and Independent Pathways

(2014) S. R. Jacobs et al.   JOURNAL OF IMMUNOLOGY

Posttranscriptional Control of T Cell Effector Function by Aerobic Glycolysis

(2013) Chih-Hao Chang et al.   CELL

Highly polarized Th17 cells induce EAE via a T-bet independent mechanism

(2013) Heather M. Grifka-Walk et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Over-expression of GAPDH in human colorectal carcinoma as a preferred target of 3-Bromopyruvate Propyl Ester

(2012) Zhenjie Tang et al.   JOURNAL OF BIOENERGETICS AND BIOMEMBRANES

3-bromopyruvate (3BP) a fast acting, promising, powerful, specific, and effective “small molecule” anti-cancer agent taken from labside to bedside: introduction to a special issue

(2012) Peter L. Pedersen   JOURNAL OF BIOENERGETICS AND BIOMEMBRANES

Current and emerging therapies in multiple sclerosis: a systematic review

(2012) Wanda Castro-Borrero et al.   Therapeutic Advances in Neurological Disorders

Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1

(2011) Eric V. Dang et al.   CELL

The Transcription Factor Myc Controls Metabolic Reprogramming upon T Lymphocyte Activation

(2011) Ruoning Wang et al.   IMMUNITY

HIF1α–dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Tregcells

(2011) Lewis Z. Shi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cutting Edge: Distinct Glycolytic and Lipid Oxidative Metabolic Programs Are Essential for Effector and Regulatory CD4+ T Cell Subsets

(2011) R. D. Michalek et al.   JOURNAL OF IMMUNOLOGY

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

(2011) Stephen Sawcer et al.   NATURE

Systemic administration of 3-bromopyruvate in treating disseminated aggressive lymphoma

(2011) Niklaus G. Schaefer et al.   Translational Research

Anticancer Targets in the Glycolytic Metabolism of Tumors: A Comprehensive Review

(2011) Paolo E. Porporato et al.   Frontiers in Pharmacology

T helper type 1 and 17 cells determine efficacy of interferon-β in multiple sclerosis and experimental encephalomyelitis

(2010) Robert C Axtell et al.   NATURE MEDICINE

Th1, Th17, and Th9 Effector Cells Induce Experimental Autoimmune Encephalomyelitis with Different Pathological Phenotypes

(2009) A. Jager et al.   JOURNAL OF IMMUNOLOGY

Localizing central nervous system immune surveillance: Meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis

(2008) Pia Kivisäkk et al.   ANNALS OF NEUROLOGY

Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival

(2008) Nancie J. MacIver et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Multiple sclerosis

(2008) Alastair Compston et al.   LANCET